ORIC PHARMACEUTICALS INC's ticker is ORIC and the CUSIP is 68622P109. A total of 83 filers reported holding ORIC PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,095,829 | -22.0% | 1,007,575 | 0.0% | 3.82% | -8.6% |
| Q2 2023 | $7,818,782 | +36.1% | 1,007,575 | 0.0% | 4.18% | +11.8% |
| Q1 2023 | $5,743,178 | -3.2% | 1,007,575 | 0.0% | 3.74% | +18.5% |
| Q4 2022 | $5,934,617 | +84.1% | 1,007,575 | 0.0% | 3.16% | +78.4% |
| Q3 2022 | $3,224,000 | -28.6% | 1,007,575 | 0.0% | 1.77% | -35.0% |
| Q2 2022 | $4,514,000 | -16.1% | 1,007,575 | 0.0% | 2.72% | +13.8% |
| Q1 2022 | $5,380,000 | -63.7% | 1,007,575 | 0.0% | 2.39% | -46.8% |
| Q4 2021 | $14,811,000 | -29.7% | 1,007,575 | 0.0% | 4.50% | -20.3% |
| Q3 2021 | $21,068,000 | +18.2% | 1,007,575 | 0.0% | 5.64% | +58.9% |
| Q2 2021 | $17,824,000 | -27.8% | 1,007,575 | 0.0% | 3.55% | -37.2% |
| Q1 2021 | $24,686,000 | -27.6% | 1,007,575 | 0.0% | 5.66% | -60.3% |
| Q4 2020 | $34,106,000 | +35.3% | 1,007,575 | -0.0% | 14.26% | +17.6% |
| Q3 2020 | $25,199,000 | -25.9% | 1,007,576 | 0.0% | 12.12% | -1.3% |
| Q2 2020 | $33,986,000 | – | 1,007,576 | – | 12.28% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Column Group LLC | 4,768,181 | $99,703,000 | 11.34% |
| Euclidean Capital LLC | 777,193 | $16,251,000 | 7.90% |
| Memorial Sloan Kettering Cancer Center | 602,272 | $12,594,000 | 7.85% |
| Invus Financial Advisors, LLC | 1,007,575 | $21,068,000 | 5.64% |
| EcoR1 Capital, LLC | 3,468,944 | $72,536,000 | 2.52% |
| EMERALD ADVISERS, LLC | 726,236 | $15,186,000 | 0.55% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 742,666 | $15,529,000 | 0.54% |
| Orbimed Advisors | 2,337,574 | $48,879,000 | 0.54% |
| Casdin Capital, LLC | 601,515 | $12,578,000 | 0.31% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 53,000 | $1,104,000 | 0.27% |